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Formenti S, Bassi M, Nakamura NB, Schoorlemmer GHM,
Menani JV, Colombari E. Hindbrain mineralocorticoid mecha-
nisms on sodium appetite. Am J Physiol Regul Integr Comp
Physiol 304: R252–R259, 2013. First published November 28,
2012; doi:10.1152/ajpregu.00385.2011.—Aldosterone acting on
the brain stimulates sodium appetite and sympathetic activity by
mechanisms that are still not completely clear. In the present study,
we investigated the effects of chronic infusion of aldosterone and
acute injection of the mineralocorticoid receptor (MR) antagonist RU
28318 into the fourth ventricle (4th V) on sodium appetite. Male
Wistar rats (280–350 g) with a stainless-steel cannula in either the 4th
V or lateral ventricle (LV) were used. Daily intake of 0.3 M NaCl
increased to 46  15 and 130  6 ml/24 h after 6 days of infusion of
10 and 100 ng/h of aldosterone into the 4th V (intake with vehicle
infusion: 2  1 ml/24 h). Water intake fell slightly and not consis-
tently, and food intake was not affected by aldosterone. Sodium
appetite induced by diuretic (furosemide) combined with 24 h of a
low-sodium diet fell from 12  1.7 ml/2 h to 5.6  0.8 ml/2 h after
injection of the MR antagonist RU 28318 (100 ng/2 l) into the 4th
V. RU 28318 also reduced the intake of 0.3 M NaCl induced by 9 days
of a low-sodium diet from 9.5  2.6 ml/2 h to 1.2  0.6 ml/2 h.
Infusion of 100 or 500 ng/h of aldosterone into the LV did not affect
daily intake of 0.3 M NaCl. The results are functional evidence that
aldosterone acting on MR in the hindbrain activates a powerful
mechanism involved in the control of sodium appetite.
aldosterone; mineralocorticoid receptor; sodium ingestion; sodium
depletion; RU 28318
SODIUM IS THE MAIN ELECTROLYTE involved in the control of
extracellular fluid osmolarity and volume and, consequently,
affects blood pressure in physiological and pathological con-
ditions. Sodium appetite, the behavior that drives animals and
humans to ingest sodium, is stimulated by body sodium defi-
ciency, a condition that usually activates the renin-angiotensin-
aldosterone system (3, 14, 32, 43, 50, 57).
ANG II and aldosterone, the two main hormones produced by
the renin-angiotensin-aldosterone system, act in the brain in a
synergistic manner to stimulate sodium appetite (13, 15, 17, 47,
50). It is well established that ANG II induces water and sodium
intake by acting on AT1 receptors located in the lamina terminalis,
in particular, in the organum vasculosum of the lamina terminalis
and the subfornical organ (4, 8, 30, 34). The mineralocorticoid
hormone aldosterone is secreted by the adrenal cortex in response
to increased level of plasma ANG II, usually in conditions of fluid
and sodium deficiency. Aldosterone acts on the kidney to reduce
renal sodium excretion and on the brain to stimulate sodium
intake (37, 41, 45, 46, 47, 49, 59, 60). In addition, it has been
suggested that aldosterone can stimulate mineralocorticoid recep-
tors (MR) in the paraventricular hypothalamic nucleus, leading to
increased sympathetic activity that may cause cardiovascular
diseases like hypertension (5, 18, 24, 25, 26, 27).
Systemic administration of aldosterone or DOCA induces so-
dium appetite, a response abolished or reduced by electrolytic
lesions or injections of antisense oligodeoxynucleotides against
MR into the amygdala (19, 37, 45, 46, 49, 60). Injections of
aldosterone or DOCA into the amygdala also induce intake of
hypertonic NaCl in next 15–30 min (46). Aldosterone-sensitive
neurons that might be involved in the control of sodium intake
have also been identified in the nucleus of the solitary tract (NTS),
close to the fourth ventricle (4th V) (20, 21). These neurons,
referred to as HSD2 neurons, coexpress MR and the enzyme 11
-hydroxysteroid dehydrogenase type 2 (HSD2) (21). The HSD2
enzyme inactivates the endogenous glucocorticoids and, thus,
allows only aldosterone to access the MR (36, 38, 39). The HSD2
neurons are activated in sodium-depleted rats and are deactivated
by sodium ingestion, which suggests that they play a role in some
aspects of sodium homeostasis (20, 21, 23).
Previous studies have investigated almost exclusively the in-
duction of sodium appetite by facilitatory signals produced the
action of ANG II or mineralocorticoids in the forebrain areas and
have assumed that the role of the hindbrain in sodium appetite is
mainly in the processing of sensory signals arising from the
periphery that inhibit sodium appetite (1, 4, 6, 7, 12, 16, 28, 29,
35, 37, 47, 49, 53, 55, 60). Considering the importance of
aldosterone and the immunohistochemical evidence such HSD2
neurons in the NTS may participate in the control of sodium
appetite, in the present study, we tested whether sodium intake is
affected by chronic infusion of aldosterone into the 4th V. Infu-
sions were made with both a syringe pump and osmotic mini-
pumps. We also tested whether bolus injections of the specific
MR antagonist RU 28318 (31) into the 4th V inhibits intake of 0.3
M NaCl. Finally, the effects of aldosterone infusions and aldoste-
rone antagonist injections into the lateral ventricle on sodium
intake were also tested.
MATERIALS AND METHODS
Animals
Male Wistar Hannover rats weighing 280 to 350 g were housed
individually and maintained in a room with controlled temperature (22
2°C), humidity (40 to 60%), and a 12:12-h light-dark cycle. Animals had
free access to tap water, 0.3 M NaCl and regular rodent chow (Nuvilab
CR1; Colombo, PR, Brazil), except when specified in the protocol. All of
the experiments were done in accordance with the Brazilian Society for
Neuroscience and Behavior Guidelines for Animal Experimentation and
were approved by the Animal Experimentation Ethics Committee of the
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Federal University of São Paulo School of Medicine (protocol no.
1805/07).
Brain Surgery
Rats were anesthetized with ketamine (100 mg/kg body wt ip) and
xylazine (10 mg/kg body wt ip) (Vetbrands, Jacareí, SP, Brazil) and
placed in a stereotaxic apparatus (Kopf, Tujunga, CA, USA). The skull
was positioned with bregma and lambda at the same horizontal level. A
23-gauge stainless-steel guide cannula was implanted in the 4th V or
lateral ventricle (LV). For the 4th V, the guide cannula was positioned on
the midline, 12.8 mm caudal to bregma, and 6.1 mm below the surface of
the skull. For the LV, the cannula was placed 0.3 mm caudal to bregma,
1.5 mm lateral to the midline, and 3.1 mm below the surface of the skull
(40). The guide cannulas were fixed to the skull with stainless-steel
screws and dental acrylic resin. An obturator closed the cannula except
during injections or infusions. At the end of the surgery, each rat received
a prophylactic dose of veterinarian antibiotic (Pentabiotico, 0.2 ml,
1:200,000 IU; Fort-Dodge, Campinas, SP, Brazil) intramuscularly. After
surgery, the animals were housed individually and allowed to recover for
8 to 10 days before the start of experiments.
Correct placement of LV cannulas was verified 5 days after surgery by
measuring the dipsogenic response to an intracerebroventricular injection
of 100 ng of ANG II. Only rats that drank at least 5 ml of water in the 10
min after injection were used to study effects of aldosterone infusion into
the LV.
Intracerebroventricular Infusions
To make tethered infusions, the obturator was removed from the
guide cannula and a 30-gauge injector, 2 mm longer than the guide
cannula, was introduced into the guide cannula. The injector was
connected with Teflon tubing to a swivel joint that was mounted
above the cage on a counterbalanced arm, allowing free movement
to the rat. A stainless-steel spring protected the tubing from
damage. The swivel joint was connected with Teflon tubing to a
100-l “airtight” Hamilton syringe (1710; Hamilton, Reno, NV)
that was mounted on a syringe pump (YA-12; Braintree Scientific,
Braintree, MA). Infusions were 2 l/h for 6 days.
Untethered infusions were made with osmotic minipumps
(model 2001; Durect, Cupertino, CA). Pumps were filled with the
solution to be infused and incubated in saline for at least 24 h at
room temperature. Rats were anesthetized with 1% halothane. The
pump was implanted under the skin in the scapular region and
connected with polyethylene tubing to an injector cannula that was
placed in the guide cannula. The injector cannula was made of 30
-gauge stainless-steel tubing bent at a 90° angle, and protruded 2
mm beyond the tip of the guide cannula. Infusions were 2 l/h for
7 days.
Intracerebroventricular Bolus Injection
Bolus injections were made with a 10-l syringe (Hamilton, Reno,
NV) connected with polyethylene (PE)-10 tubing to an injector made
Fig. 1. Intakes of hypertonic NaCl, water, and food by rats that received long-term infusion of aldosterone into the brain ventricles with a syringe pump. Daily
intake of 0.3 M NaCl (A), daily water intake (B), and daily food intake (C) by rats that received aldosterone infusion into the 4th ventricle. D: daily intake of
0.3 M NaCl by rats that received aldosterone infusion into the lateral ventricle (LV). Error bars show means  SE. *Significantly different from vehicle (P 
0.05). /Significantly different from aldosterone 1 ng/h. Significantly different from aldosterone 10 ng/h.
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from a 30-gauge needle. The injector, when fully inserted, protruded
2 mm (4th V) or 1.5 mm (LV) beyond the tip of the guide cannula.
Injections were 2 l in about 30 s.
Drugs Injected
Aldosterone (Sigma, St. Louis, MO) was prepared at concentra-
tions of 0.5, 5, 50, and 250 g/ml. RU 28318 (MR antagonist, Tocris
Bioscience, Ellisville, MO) was prepared at a concentration of 100
ng/2 l (10, 11, 31, 47). Solutions of aldosterone were made fresh
from a stock solution of 20 mM of aldosterone maintained in a
refrigerator. Vehicle for aldosterone and RU 28318 was 1% ethanol in
0.9% NaCl.
Measurement of Intakes of 0.3 M NaCl, Water, and Food
In experiments with chronic infusions, rats had free access to water
and 0.3 M NaCl in burettes with 1-ml divisions that were fitted with
metal drinking spouts. A preweighted amount of regular pelleted
chow was made available. Spilled chow was collected and considered
in the calculation of food intake. Intakes of water, 0.3 M NaCl, and
food were measured each 24 h.
For measurement of intakes in 2-h intake tests, water and 0.3 M
NaCl were presented in burettes with 0.1-ml division fitted with metal
drinking spouts. Intakes of water and 0.3 M NaCl were measured at
15, 30, 60, 90, and 120 min after the access to the fluids.
Histology
At the end of experiments, rats were deeply anesthetized with a
lethal intraperitoneal dose of urethane (Sigma, St. Louis, MO) and
then received an injection of Evan’s blue dye (100 nl of a 2% solution)
into the 4th V or LV. Rats were perfused transcardially with 10%
formalin. The brain was removed, stored in buffered formalin for at
least 2 days, and cut in 50-m coronal sections with a microtome.
Slices were stained by the Giemsa method and analyzed by light
microscopy. Only rats with clear spread of dye in the LV or 4th V
were used for data analysis.
Statistical Analysis
The results are shown as means  SE. Intakes in tests with
long-term infusion of aldosterone were compared by two-way
ANOVA, with factors drug dose and time. Intakes after 9 days of
low-sodium diet similarly were compared by two-way ANOVA.
Intakes after treatment with furosemide followed by 24 h without
access to sodium were compared by two-way repeated-measures
ANOVA. Significant ANOVAs were followed by Tukey’s post hoc
test. Body weights before and after the treatments were compared with
paired t-tests Statistical analyses were performed with SigmaStat 2.0
software (Jandel, Point Richmond, CA). The level of significance was
set at P  0.05.
Experimental Protocols
Hypertonic NaCl and water intake by rats treated with chronic
infusion of aldosterone in the 4th or LV. Infusions were made either
with a syringe pump or with an implantable osmotic minipump. In
experiments with syringe pump infusions, daily ingestion of food,
water, and 0.3 M NaCl were recorded for a period of 12 days that
included a 3-day preinfusion control period, a 6-day period of con-
tinuous infusion, and a 3-day postinfusion recovery period. Infusions
into the 4th V contained either vehicle (2 l/h) or 1, 10, or 100 ng/h
of aldosterone (n  5/dose). Infusions into the LV contained either
vehicle or 10 or 100 ng/h aldosterone (n  4/dose). Body weight was
measured just before the start of the infusion and immediately after
the end of the infusion. Each rat received only one type of infusion.
In experiments with osmotic minipump infusions, daily intakes of
water and 0.3 M NaCl were recorded for a period of 13 days that
included a 3-day preinfusion control period, 7 days of infusion, and a
3-day postinfusion recovery period. Infusions into the 4th V contained
100 ng/h of aldosterone (n  5). Infusions in the LV contained 100 or
500 ng/h of aldosterone (n  5 or 6). Each rat received only one type
of infusion.
Sodium depletion-induced hypertonic NaCl intake by rats treated
with a bolus injection of aldosterone antagonist into the 4th V or LV.
Rats were depleted of sodium with two injections of the diuretic
furosemide (Hipolabor, Sabará, MG, Brazil), which were each 10
mg/kg body wt sc, made with a 30-min interval of each other. Then,
the rats were kept with access only to water and a low-sodium diet for
the next 24 h. After this period, the rats received a single injection of
vehicle or RU 28318 (100 ng/2 l) into the 4th V (n  6/group) or
into the LV (n 6/group). Two hours after the injection, access was
allowed to graduated tubes containing water and 0.3 M NaCl.
Water and 0.3 M NaCl intakes were measured at 15, 30, 60, 90, and
120 min. The rats were sodium-depleted once a week during 3 wk.
The first sodium depletion was used only for training, rats received
no central injection, and data were not analyzed. On the second and
the third depletion, rats received the drug and the vehicle in
random order.
Low-sodium diet-induced hypertonic NaCl intake by rats treated
with bolus injection of aldosterone antagonist into the 4th V. Rats had
free access to low-sodium chow (0.005% Na; Prag Soluções Bio-
ciências, Jaú, SP, Brazil) and distilled water for 9 days. After this
Table 1. Body weight immediately before and after 6 days of
intracerebroventricular infusion of aldosterone
Initial Weight, g Final Weight, g
4th Ventricle infusion
Vehicle (5) 347 11 346 10
Aldo 1 ng/h (5) 343  11 356 9
Aldo 10 ng/h (5) 330  15 325 16
Aldo 100 ng/h (5) 320  9 313 12
LV infusion
Aldo 10 ng/h (4) 296  6 310 6
Aldo 100 ng/h (4) 290  4 298 8
Data are expressed as means  SE. Values in parentheses show the number
of animals. Aldo, aldosterone; LV, lateral ventricle.
Table 2. Water intake during 6 days of infusion of aldosterone into the LV
Days
1 2 3 4 5 6
Vehicle 33.3 2.3 30.3  2 35.5  2.2 29.7  1,1 32.1 1 29  0.5
Aldo, 10 ng/h 27.8  2.2 25.5  1.9 28.7  1.9 27.1  2.2 30.1 2.5 35.2  5.1
Vehicle 30.2 1.4 30.1  3.4 26.7  1.6 26.2  3.4 25.4 3.7 26  4
Aldo, 100 ng/h 24.6  3.5 26.2  3.5 26.2  2.5 25.4  2.9 24.4 3.5 22.9  3.1
Data are expressed as means  SE; n  4 rats in each group.
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period, the rats randomly received an injection of vehicle (n  4) or
RU 28318 (100 ng/2 l, n  5) into the 4th V. Two hours after the
injection into the 4th V, access was allowed to graduated tubes
containing distilled water and 0.3 M NaCl. Water and 0.3 M NaCl
intake was measured at 15, 30, 60, 90, and 120 min.
RESULTS
Intakes of hypertonic NaCl, water, and food by rats treated
with chronic infusion of aldosterone into the 4th and LV. In
experiments with tethered rats (syringe infusion), infusion of
aldosterone into the 4th V caused a dose-dependent increase in
daily intake of 0.3 M NaCl, with significant differences be-
tween treatments [F(3, 192)  126.89; P  0.001] (Fig. 1A).
The highest dose of aldosterone (100 ng/h) induced strong
daily ingestion of 0.3 M NaCl, with intakes reaching 130  6
ml/24 h on the 6th day of infusion (Fig. 1A). After the end of
the infusions, NaCl intake rapidly (within 24 h) returned to
baseline levels (Fig. 1A). This high dose of aldosterone was
significantly more effective than lower doses (1 or 10 ng/h)
from the 3rd to 6th day of infusion. Infusion of 10 ng/h induced
0.3 M NaCl intakes of up to 46  15 ml/24 h on 5th day of
infusion. This dose was significantly more effective than the
lowest dose (1 ng/h) from the 4th to 6th day of infusion. The
1 ng/h dose of aldosterone produced only small 0.3 M NaCl
intakes (up to 9  3 ml/24 h on the 6th day of infusion, Fig.
1A), but this was not significantly different from vehicle.
Water intake fell with aldosterone infusions in the 4th V,
with a significant difference between the 10 ng/h group and
vehicle on day 6 of infusion [F(3, 192)  11.15; P  0.001]
(Fig. 1B). On the 3rd and 6th day of infusion, this dose of
aldosterone also reduced water intake compared with the low-
est dose of aldosterone (1 ng/h). The highest dose of aldoste-
rone (100 ng/h) reduced daily water intake compared with the
lowest dose of aldosterone (1 ng/h) on the 4th day of infusion.
Aldosterone (1, 10, or 100 ng/h) did not change daily food
intake (Fig. 1C) or body weight (Table 1).
In contrast with 4th V infusions, LV infusions (10 or 100
ng/h of aldosterone for 6 days) failed to stimulate daily intake
of 0.3 M NaCl [F(2,108) 1.05; P 0.05] (Fig. 1D). Infusion
of aldosterone into the LV also did not alter body weight and
daily water or food intake (Tables 1, 2, and 3).
Infusion of aldosterone (100 ng/h) into the 4th V with
osmotic minipumps induced 0.3 M NaCl intakes of up to
50.7  5.9 ml/24 h on the 7th day of infusion, which differed
from the baseline period from the 4th to 7th day of infusion
[F(2, 128) 73.97; P 0.0001] (Fig. 2A). After the end of the
infusions, 0.3 M NaCl intake rapidly (within 24 h) returned to
baseline levels (Fig. 2A). This 4th V infusion did not change
daily water intake.
Infusion of aldosterone (100 and 500 ng/h) into the LV with
osmotic minipumps did not affect daily intake of 0.3 M NaCl
(Fig. 2A) or water (Fig. 2B).
Sodium depletion-induced hypertonic NaCl intake by rats
treated with bolus injection of aldosterone antagonist into the
4th V and LV. Injection of the aldosterone antagonist RU
28318 (100 ng/2 l) into the 4th V reduced 0.3 M NaCl intake
induced by 24 h of sodium depletion (furosemide followed by
Table 3. Food intake during 6 days of infusion of aldosterone into the LV
Days
1 2 3 4 5 6
Vehicle 22 1.2 23.1  1.1 27.7  2.6 22.6  0.3 22.7 2.1 24.7  0.9
Aldo, 10 ng/h 27  2.6 24.3  1.9 27.1  2.8 27.5  2.2 29.6 2.5 25.9  1.4
Vehicle 21.3 1.2 23.5  3.4 21  1.7 21.4  2.6 21.4 2.4 21.9  1.8
Aldo, 100 ng/h 22.1  3.1 23  3.3 21.4  4 24.9  2.3 23.9 1.4 22.4  1.9
Data are expressed as means  SE; n  4 rats in each group.
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Fig. 2. Intakes of hypertonic NaCl and water by rats that received long-term
infusion of aldosterone into the brain ventricles with osmotic minipumps.
Daily intake of 0.3 M NaCl (A) and daily water intake (B) by rats that received
infusions of aldosterone into the LV and fourth ventricle (4th V). Error bars
show means  SE. *Significantly different from the intake in the baseline or
recovery period in the same group (P  0.05). Significantly different from
aldosterone infused into the LV (P  0.05).
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24 h without access to sodium) (5.6  0.8 ml/2 h vs. vehicle:
12  1.7 ml/2 h) [F(1, 5)  22.54; P  0.05] (Fig. 3A). Water
intake was not affected by RU 28318 [F(1, 5)  1.72; P 
0.05] (Fig. 3B). Injection in the LV of this dose of RU 28318
did not affect sodium depletion-induced intake of 0.3 M
NaCl (14.8  2.8 vs. vehicle: 15.1  3 ml/2 h) [F(1, 5) 
0.19; P  0.05] and water [F(1, 5)  0.56; P  0.05] (Fig.
3, C and D).
Low-sodium diet-induced hypertonic NaCl intake by rats
treated with bolus injection of aldosterone antagonist into the
4th V. Injection of RU 28318 (100 ng/2 l) into the 4th V
abolished 0.3 M NaCl intake induced by 9 days of low-sodium
diet (1.2  0.6 vs. vehicle: 9.5  2.6 ml/2 h) [F(1, 35) 
47.69; P  0.001] (Fig. 4A). Sodium-deprived rats drank
little water, but water intake was further reduced by RU
28318 (0.1  0.1 vs. vehicle: 0.5  0.1 ml/2 h) [F(1, 35) 
20.86; P  0.001] (Fig. 4B).
DISCUSSION
The present results show that chronic infusion of aldosterone
into the 4th V induced strong daily ingestion of hypertonic
NaCl without changing food intake or body weight, whereas
the injection of the specific MR antagonist RU 28318 into the
4th V reduced NaCl intake induced by either 24 h of sodium
depletion or low-sodium diet. Water intake was not consis-
tently affected by these treatments. These results suggest that
mineralocorticoid mechanisms in the hindbrain are important
for the control of sodium intake.
Although both methods used to infuse aldosterone into the
4th ventricle induced a strong sodium appetite, syringe infu-
sions produced larger intakes and possibly a faster onset of
sodium appetite. With osmotic minipumps, infusions were
delayed by the time required for the drug to pass the infusion
tubing and injection cannula, whereas syringe infusions did not
have this delay. Also, drug degradation may be less of a factor
with syringe infusions, as infusion solutions were prepared
fresh every day.
Whereas the administration of aldosterone or MR antagonist
into the 4th V caused large changes in hypertonic NaCl intake,
the administration in the LV had no effect. A similar difference
between effects of infusion of aldosterone into the LV and
more caudally has been reported for sodium excretion. Aldo-
sterone induces natriuresis when infused in the subcomissural
organ region, close to the aqueduct, but not when infused in the
LV (10, 11). In contrast to our finding that a bolus injection of
a MR antagonist into the LV did not reduce sodium intake, it
Fig. 3. Intake of water and 0.3 M NaCl induced by 24 h of sodium depletion in rats treated with bolus injection of the mineralocorticoid receptor antagonist RU
28318 (100 ng at t  	2 h) into the brain ventricles. A and B: intake of 0.3 M NaCl and water by rats that received injection into the 4th V. C and D: intake
of 0.3 M NaCl and water by rats that received injection into the LV. Error bars show means  SE. *Significantly different from vehicle.
R256 ALDOSTERONE AND SODIUM APPETITE
AJP-Regul Integr Comp Physiol • doi:10.1152/ajpregu.00385.2011 • www.ajpregu.org
has been reported that continuous infusion of MR antagonists
(spironolactone or RU 28318) into the LV for one or more days
reduced sodium intake in rats (16, 47, 53). The different effects
of LV and 4th V infusions might be related to the ease with
which drug reaches the sites involved in the control of sodium
intake. It is well known that forebrain areas, such as the
amygdala are involved in aldosterone-induced sodium intake
(16, 45, 46, 47, 53). However, the distance between the
amygdala and the LV is significant, and this may prevent an
easy access to the amygdala by drugs injected in the LV. In
contrast, the NTS, and, particularly, the HSD2 neurons in this
area are located close to the 4th V and might be easily affected
by drugs injected into the 4th V (20, 21). Although the present
results suggest that hindbrain mineralocorticoid mechanisms
are involved in the control of sodium intake, they are not
incompatible with a role for mineralocorticoid receptors in the
amygdala.
Earlier studies suggested that the amygdala is a main central
site activated by aldosterone to induce sodium appetite (37, 45,
46, 60). Salt appetite is elicited in normohydrated and satiated
rats immediately after the injection of aldosterone or DOCA
into the amygdala and the administration of antisense oligode-
oxynucleotides against MR into the amygdala reduced DOCA-
induced sodium intake (45, 46). More recent neuroanatomical
studies have shown aldosterone-sensitive neurons (HSD2 neu-
rons) in the NTS that are activated in sodium-depleted rats and
deactivated by hypertonic NaCl ingestion, suggesting that
these neurons play a role in body sodium homeostasis (20, 21,
22). These neurons are located in the medial border of the NTS
close to the 4th V (20, 21, 22), and therefore, they might be
easily affected by aldosterone and MR antagonists infused into
the 4th V. Therefore, the present functional results complement
previous neuroanatomical studies (20, 21, 22, 23), suggesting
that hindbrain MR receptors located close to the 4th V (pos-
sibly on HSD2 neurons in the NTS) are important for aldoste-
rone-induced sodium intake.
Aldosterone infused into the 4th V may produce natriorexi-
genic responses by directly activating facilitatory mechanisms
or by modulating inhibitory mechanisms like the lateral para-
brachial nucleus (LPBN) mechanisms that are thought to de-
pend on NTS signals (4, 34, 35). It seems less likely that
increased intake is a consequence of renal sodium loss, al-
though chronic central infusion of aldosterone into the region
of the subcommissural organ, close to the aqueduct, is known
to induce natriuresis (10, 11). In addition, the acute inhibition
of sodium intake by injection of MR antagonist into the 4th V
suggests that the activation of sodium intake by hindbrain MR
does not depend on natriuretic effects of aldosterone acting on
the brain stem.
Although the infusion of aldosterone in the 4th V induced
intake of large volumes of hypertonic NaCl, it failed to in-
crease water intake. In fact, infusion of 10 ng/h of aldosterone
tended to reduce water intake. The mechanism of this reduced
water intake is not yet clear. As discussed above, central
infusion of aldosterone may produce natriuresis (10, 11), and
reduced plasma sodium may facilitate sodium intake and in-
hibit water intake. Intake of hypertonic NaCl increases plasma
sodium, and this usually drives rats to ingest water. Sodium-
depleted rats ingest a small (less than 3 ml in a 2-h test) amount
of water when they have access to 0.3 M NaCl (49, 50, 51, 52).
As this water intake is small and highly variable, differences on
water intake in these tests are usually not statistically signifi-
cant, as in the present study.
A synergism between aldosterone and ANG II in the control
of sodium appetite has been suggested, and the complete
suppression of sodium depletion-induced sodium intake re-
quires a combination of blockade of central MR and ANG II
action (13, 15, 47, 50). In the present study, the injection of a
MR antagonist into the 4th V almost abolished sodium intake
induced by a low-sodium diet, whereas sodium intake induced
by 24 h of sodium depletion fell by only 50%, suggesting that
sodium intake after 9 days of dietary sodium depletion depends
more on mineralocorticoid mechanisms. Sodium appetite in
rats treated with furosemide is known to depend on increased
circulating ANG II (9, 17, 44) and, therefore, sodium appetite
remaining in these rats after the blockade of hindbrain MR
might be due to ANG II or possibly to MR receptors in the
forebrain that may still act in a synergism with ANG II (15,
50, 54).
The actions of mineralocorticoids in the brain involve both
rapid nongenomic mechanisms dependent on cell membrane
MRs and slow genomic mechanisms that depend on cytosolic
MRs. Both mechanisms are thought to be involved in the
control of sodium intake (46, 47, 56). The genomic mecha-
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nisms and the synergism between aldosterone and ANG II
might explain why a strong ingestion of hypertonic NaCl arises
only several hours after sodium depletion, like the ingestion of
sodium by 24-h sodium-depleted rats (44). The ingestion of
small volumes of 0.25 M NaCl (2 to 3 ml in 30 min) induced
by aldosterone injection into the amygdala (46) and the reduc-
tion of sodium appetite 2 h after injection of RU 28318 into the
4th V (present results) suggest the involvement of nongenomic
mechanisms. The daily increase in sodium intake during 6 days
of aldosterone infusion into the 4th V might be the result of
cumulative activation of the genomic mechanisms. However,
sodium intake returned to control levels shortly after stopping
aldosterone infusion, which would not be expected if genomic
mechanisms were involved in this behavior.
In conclusion, the present study shows that infusion of
aldosterone into the 4th V induces strong daily ingestion of
sodium, whereas a MR antagonist injected into the 4th V
reduces sodium intake induced by either 24 h of sodium
depletion or chronic low-sodium diet. The results suggest that
the MR receptors located in the hindbrain close to the 4th V
(possibly HSD2 neurons in the NTS) are part of the mecha-
nisms involved in the natriorexigenic response produced by
aldosterone.
Perspectives and Significance
Important facilitatory and inhibitory mechanisms involved
in the control of sodium appetite have been described in the
forebrain and hindbrain. The present study suggests that im-
portant mineralocorticoid mechanisms involved in the control
of sodium intake are present in the hindbrain. Interactions
between forebrain and hindbrain mechanisms involved in the
control of sodium intake probably exist, and an understanding
of how the hindbrain interacts with the forebrain in the control
of salt appetite and also the relative importance of forebrain
and hindbrain MRs in the control of sodium intake are the
challenges for the future research. Activation of MR may also
increase sympathetic activity in animals and in hypertensive
patients (5, 18, 24, 25, 26, 27, 58). The NTS that harbors the
HSD2 neurons activated by aldosterone is an important site for
the control of sympathetic nerve activity. Therefore, future
studies might investigate whether the intense sodium appetite
produced by the action of aldosterone on the hindbrain is
accompanied by aldosterone-induced sympathetic activation.
This combination of effects may make aldosterone a particu-
larly effective hypertensive factor in the case of unbalanced
secretion of this hormone.
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